Christopher E. Ware, who serves as Senior Vice President, General Counsel, and Corporate Secretary at ITRON, INC. (NASDAQ:ITRI), conducted a sale of company stock on May 20, 2026. Specifically, Mr. Ware sold 189 shares of the company's common stock, resulting in a total transaction value of $15,043.
The divestment was executed at an agreed price of $79.5976 per share. Records indicate that this sale represented automatically disposed shares necessary to cover tax withholding obligations associated with the vesting of a restricted stock unit award. Following this specific transaction, Mr. Ware's direct ownership stake in Itron common stock stood at 30,506 shares.
The recent share movement occurred when the stock was trading near its 52-week low of $77.77, although subsequent market activity saw the price rebound to $82.31. From a valuation perspective, an analysis provided by InvestingPro suggests that ITRI may currently be undervalued, citing a Price-to-Earnings (P/E) ratio of 13.12. This platform further offers investors eight additional ProTips aimed at providing deeper insights into the company's $3.66 billion market valuation.
Beyond this insider activity, Itron Inc. recently disclosed its financial results for the first quarter of 2026. The company reported earnings per share (EPS) of $1.49, a figure that exceeded the consensus analyst forecast of $1.23. Revenue also surpassed expectations, reaching $587 million when analysts had projected $572.09 million.
Despite these positive figures regarding both quarterly earnings and revenue generation, the stock encountered a decline during pre-market trading. This downturn reflected investor concerns pertaining to certain aspects of the company's performance. Adding complexity to the financial narrative, Roth/MKM adjusted its price target for Itron. The firm lowered this target from $150 to $136, while simultaneously maintaining a Buy rating on the stock.
The rationale provided for lowering the price target centered on Itron's more subdued near-term revenue growth. This slower projected growth is attributed by the analysts to factors including complex projects and temporary regulatory elements. Collectively, these varied developments underline a mixed sentiment surrounding Itron’s immediate financial outlook.
Key Points and Market Impact
- <li class="risk">The stock experienced a decline in pre-market trading despite positive earnings results, indicating underlying investor concerns about specific performance aspects.</li>
- <li class="risk">Analyst Roth/MKM adjusted its price target downward from $150 to $136 due to subdued near-term revenue growth attributed to complex projects and temporary regulatory factors.</li>